Related Experiment Video

Updated: Jun 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

[Antiproliferation of cardamonin associated with mRNA expression of mTOR, Raptor and Rictor]

Wei Zheng1, Daohua Shi, Xiangfu Ji

  • 1Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, China. kathy8329@163.com

Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
|December 9, 2010
PubMed
Abstract

Insights

Cardamonin (CAR) effectively inhibits the proliferation of human umbilical artery smooth muscle cells (HUASMCs), particularly in insulin-resistant conditions. This antiproliferative effect is linked to the downregulation of mTOR, Raptor, and Rictor gene expression.

Area of Science:

  • Vascular Biology
  • Pharmacology
  • Cell Biology

Background:

  • Insulin resistance (IR) significantly increases human umbilical artery smooth muscle cell (HUASMC) proliferation.
  • HUASMCs play a critical role in vascular tone and are implicated in cardiovascular complications associated with IR.

Purpose of the Study:

  • To investigate the antiproliferation effects of cardamonin (CAR) on HUASMCs.
  • To elucidate the underlying molecular mechanisms of CAR's action in an IR-mimicking environment.

Main Methods:

  • HUASMC proliferation was assessed using the MTT assay.
  • mRNA expression levels of mTOR, Raptor, and Rictor were quantified via real-time PCR.
  • The impact of CAR on cell proliferation and gene expression was evaluated in normal and IR-mimicking media.

Main Results:

  • CAR demonstrated significant antiproliferative activity against HUASMCs in both normal and IR-mimicking conditions.
  • CAR treatment led to a notable decrease in the mRNA expression of mTOR, Raptor, and Rictor in the IR-mimicking medium.
  • Inhibition of proliferation induced by phosphatidic acid (PA) was observed with PD98059 and LY294002 pretreatment.

Conclusions:

  • Cardamonin exhibits antiproliferative effects on HUASMCs.
  • The mechanism involves the downregulation of mRNA expression for mTOR and its associated proteins, Raptor and Rictor.
  • CAR holds potential as a therapeutic agent for conditions involving vascular smooth muscle cell hyperproliferation in insulin resistance.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...